Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||BNT111 + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BNT111||BNT-111|BNT 111||BNT111 is a liposomal RNA vaccine comprising mRNA transcripts that encode wild-type NY-ESO1, MAGE-A3, TYR (aa 1-477), and TPTE tumor specific antigens (TSAs), which is targeted to and expressed in dendritic cells, potentially inducing cytotoxic T-cell response against NY-ESO1, MAGE-A3, TYR, and TPTE expressing tumor cells (PMID: 32728218).|
|unspecified PD-1 antibody||Experimental PD-1 antibody||Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|